Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mary Wells (NPI 1538508296)

Field	Value
Entity Type	Individual
Organization	Mary Wells
Address	8303 Dodge St Ste 250
City	Omaha
State	NE
ZIP	68114
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 17, 2013

Payer Source	Total Paid
Medicare	$935.6K
Medicaid	$0

Key Findings

This provider’s Medicare revenue totals $935.6K with no Medicaid billing on file, making their publicly observed practice effectively single-payer (Medicare) in scope. The absence of any Medicaid claims indicates either no participation in that program or no billed Medicaid volume during the reporting period, so payer-mix analysis should treat this entity as primarily Medicare-driven.

Revenue concentration is extremely high: the top three Medicare codes account for 88.1% of the provider’s total Medicare revenue. The majority of that concentrated revenue is tied to J9271, which alone represents $662.3K (71.7% of Medicare revenue), signaling that a single high-cost drug is the dominant revenue driver for this clinician.

The code mix—dominated by J9271 (pembrolizumab) and supplemented by J1449 (eflapegrastim-xnst) and E/M code 99214—indicates a hematology/oncology practice focused on high-cost oncology drug administration combined with outpatient medical management. High volumes of drug administration codes such as 96413, 96417, and add-on chemotherapy administration codes further support that the practice delivers infusion-based cancer therapies rather than primarily office-based primary care.

On competitive standing for major revenue codes, the provider is a modest to typical national participant: J9271 volume ranks #650 of 1841 providers (65th percentile), described as typical, and J1449 ranks #63 of 161 providers (58th percentile), also typical. For E/M visits like 99214 the provider sits at the 93rd percentile by rank (#35137 of 479517), which is relatively strong nationally for that office-visit code and suggests a consistent level of outpatient management activity compared with peers.

Tenure: this NPI has been enumerated since 2013-06-17 (~13 years ago), indicating an established billing history that aligns with a sustained specialty practice rather than a recent entrant. That length of enrollment supports interpretation of patterns (for example, long-term reliance on oncology drug administration) as persistent rather than transient.

Although many infusion- and oncology-related administration codes appear at typical volumes by national percentile, several supportive services—such as 96367, 96375, and 96365—also appear across the top-25 list, reflecting routine use of sequential and initial infusions typical of oncology infusion centers. These lower-dollar but frequent infusion codes collectively reinforce the operational model of repeat IV infusions for cancer care.

Given the dominance of a single high-cost biologic (J9271) in revenue mix, this provider’s financial exposure and operational focus are concentrated on pembrolizumab administration. Payer negotiations, formulary shifts, or changes in oncology treatment patterns for that drug would therefore likely have a disproportionate effect on the provider’s Medicare revenue.

National percentile ranks for many chemotherapy and infusion codes are in the middle-to-upper range (for example, 96413 at the 78th percentile and 96375 at the 72nd percentile), which indicates consistent, above-average chemotherapy administration activity relative to national peers but not at the level of a top outlier. This positions the practice as a reliable regional contributor of oncology infusion services rather than an unusually high-volume national hub.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

41 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	15,400	$40	$662.3K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	3,960	$30	$99K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	600	$90	$53.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	320	$90	$30.5K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	110	$130	$14.1K
J1439	Injection, ferric carboxymaltose, 1 mg	12,750	$1	$12.8K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	50	$110	$5.9K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	30	$160	$5.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	80	$60	$4.6K
96417	In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy…	80	$50	$3.8K

Showing 1–10 of 41

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 41 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Mary Wells — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

41 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	12	30	14,400	$40	$671.6K
J1449	3	10	3,700	$30	$92.4K
J1439	27	30	25,880	$1	$26.4K
96413	24	80	60	$90	$18.2K
99214	245	3,210	110	$70	$14.9K
99233	656	830	80	$90	$11.7K
J3490	8	30	60	$160	$11.3K
96401	31	30	120	$50	$11K
99232	827	1,390	80	$60	$8.6K
99213	1,713	3,220	90	$50	$7.9K

Showing 1–10 of 41

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mary Wells, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Stefano Tarantolo	NE	Hematology & Oncology Physician	$3.2M	$0
Samuel Mehr	NE	Nuclear Medicine Physician	$2.5M	$0
Ralph Hauke	NE	Hematology & Oncology Physician	$2.5M	$0
Gamini Sooriyaarachchi	FL	Medical Oncology Physician	$2.2M	$0
Ryan Ramaekers	NE	Hematology & Oncology Physician	$2.1M	$0
Joel Michalski	NE	Internal Medicine Physician	$2M	$0
Yungpo Su	NE	Hematology & Oncology Physician	$1.9M	$0
Margaret Block	NE	Hematology & Oncology Physician	$1.7M	$0
Robert Langdon	NE	Hematology & Oncology Physician	$1.4M	$0
Muhammad Haroon	NE	Hematology & Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Mary Wells, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Children's Hospital & Medical Center	NE	Children's Hospital	$0	$89.8M
Children's Physicians	NE	Pediatrics Physician	$0	$39.4M
Nebraska Pediatric Practice, Inc	NE	Pediatrics Physician	$0	$29M
Physicians Clinic Inc	NE	Family Medicine Physician	$0	$20.5M
Nebraska Methodist Hospital	NE	General Acute Care Hospital	$0	$14.5M
Smiles 4 Kids PC	NE	General Practice Dentistry	$0	$11.5M
Children's Hospital	NE	Pediatric Emergency Medicine (Pediatrics) Physician	$0	$8.4M
Nebraska Methodist Hospital	NE	Emergency Medicine Physician	$0	$5.3M
Unmc College Of Dentistry	NE	Dentist	$0	$4.8M
Stones Worth Stepping, P.C.	NE	Occupational Therapist	$0	$4.7M

Mary Wells — Billing Profile & Reimbursement Data

Sign up for Mary Wells — Billing Profile & Reimbursement Data policy alerts

Mary Wells — Billing Profile & Reimbursement Data

Sign up for Mary Wells — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References